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The ability of interleukin-10 therapy to reduce the
severity of exacerbated psoriasis has been demon-
strated recently. Considering the immunobiologic
properties of this cytokine we investigated the effects
of long-term interleukin-10 application on the
immune system and duration of psoriasis remission.
We performed a placebo-controlled, double-blind,
phase II trial using interleukin-10 in patients with
chronic plaque psoriasis in remission. Patients
received subcutaneous injections with either interleu-
kin-10 (10 mg per kg body weight; n = 7) or placebo
(n = 10) three times per week until relapse or study
termination after 4 months. The treatment was well
tolerated. In the placebo group almost all patients
(90%) showed a relapse during the observation per-
iod. In contrast to this, only two of seven patients
(28.6%) relapsed in the interleukin-10-treated group.
Kaplan±Meier analysis revealed a signi®cantly lower
relapse incidence in the interleukin-10 than in the
placebo group (p = 0.02). The mean relapse-free
interval time was 101.6 6 12.6 d in the interleukin-10
group in comparison with 66.4 6 10.4 d in the pla-
cebo group. Immunologic activity of interleukin-10
application was indicated by an increase in soluble
interleukin-2 receptor plasma levels and higher ex vivo
interleukin-4 secretion capacities. Remarkably, a sig-
ni®cant negative correlation was demonstrated
between the interleukin-4 secretion capacity and
Psoriasis Area and Severity Index score (r = ±0.36,
p < 0.01). Our data suggest that interleukin-10 ther-
apy is immunologic effective, decreases the incidence
of relapse and prolongs the disease-free interval in
psoriasis. Its value should be further determined in
larger trials and for the prevention of re-exacerbation
of other in¯ammatory disorders with a similar immu-
nologic pro®le. Key words: immunotherapy/interleukin-
10/psoriasis/relapse prevention. J Invest Dermatol 118:672±
677, 2002
O
wing to its considerable anti-in¯ammatory and
immunosuppressive capacities interleukin (IL)-10
became a candidate for the therapy of several
immune diseases. The ®rst administration of human
recombinant IL (rhIL)-10 in humans was per-
formed in healthy volunteers in 1995 (Chernoff et al, 1995). The
®rst successful therapeutic IL-10 treatment was reported in patients
with steroid-refractory Crohn's disease (Van Deventer et al, 1997).
Soon thereafter, Wissing et al (1997) demonstrated anti-in¯amma-
tory effects of rhIL-10 application in kidney transplant recipients
receiving induction therapy with the monoclonal anti-T cell
antibody OKT3.
Psoriasis is a common, chronically relapsing, T cell dependent
(auto)immune disease characterized by a type 1 cytokine pattern
(Valdimarsson et al, 1986; Uyemura et al, 1993). Recently, we
started to study the therapeutic effect of rhIL-10 in psoriatic
patients in a pilot trial (Asadullah et al, 1998). Daily injections of
8 mg rhIL-10 per kg body weight directly under a psoriatic plaque
over a 24 d period led to complete clearance of the plaque in one of
two patients. Moreover, some systemic anti-psoriatic effects were
observed in all patients treated in this pilot trial, including the third
patient receiving subcutaneous injections under nonlesional skin.
The immunosuppressive effects (decrease of monocytic human
leukocyte antigen-DR expression, IL-12 plasma levels, and
responsiveness to recall antigens) as well as a shift towards a type
2 cytokine pattern (increasing proportion of IL-4 producing T cells,
increase in immunoglobulin E serum levels), which we observed in
all three patients, might be the basis for the observed anti-psoriatic
activity of IL-10. As these ®ndings suggested that IL-10 treatment is
safe and might be effective, its anti-psoriatic effect was further
investigated. In an open label phase II clinical trial, 10 psoriatic
patients received subcutaneously rhIL-10 over a 7 wk period in a
daily dosage of 8 mg per kg (n = 5) or 20 mg per kg three times per
week (n = 5), respectively (Asadullah et al, 1999a). Patients were
followed up for an additional 7 wk. The treatment was well
tolerated. Anti-psoriatic effects were found in nine of 10 patients
resulting in a signi®cant decrease of the psoriasis area and severity
index (PASI) by over 50%. The anti-psoriatic effect was con®rmed
by histologic examination. A similar clinical effectiveness of IL-10
application was recently reported by Reich and coworkers (Reich
et al, 1998; Asadullah et al, 2001a; Reich et al, 2001). These results
suggest that IL-10 therapy in psoriasis over up to 7 wk is safe and
clinically ef®cient to treat psoriasis exacerbation.
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In contrast to treatment of an acute exacerbation of psoriasis the
existing therapeutic options to prevent the reoccurrence of the
disease are rather limited. Long-term applications of cyclosporine
A, methotrexate or retinoids are frequently associated with partly
severe side-effects, indicating the important medical need for novel
long-term therapeutic options (Asadullah et al, 1999b). This would
also reduce the cost-intensive morbidity and frequent hospitaliza-
tion characteristic for patients with severe psoriasis.
Based on the promising results of IL-10 short/medium-term
application and the observed long-lasting immunomodulatory
effects of IL-10 treatment (Asadullah et al, 1998) it was hypothesized
that low-dose long-term IL-10 maintenance treatment might
represent a novel therapeutic regimen to prevent the rapid
reoccurrence of lesions after successful conventional anti-psoriatic
therapy in patients with severe remittent psoriasis. The aim of this
trial was to collect initial data on the safety, immunologic effects and
the clinical response to long-term low-dose subcutaneous IL-10
application after remission of psoriasis. We analyzed whether long-
term IL-10 treatment is effective to extend the duration of remission
or is even able to prevent the relapse of psoriasis at all. Such a
secondary prophylactic approach is clearly different from the
therapeutic approaches performed with IL-10 so far, all targeting
on exacerbated established diseases. For the prolongation of the
relapse-free interval in patients with psoriasis the long-term
immunomodulatory effects of IL-10 rather than its direct anti-
in¯ammatory activity should mainly determine the ef®cacy.
MATERIALS AND METHODS
Study protocol and patients A placebo-controlled, randomized,
double-blind, comparative early phase II clinical trial with recombinant
human IL-10 (SCH 52000; kindly provided by Essex Pharma, Munich,
Germany/Schering Plough Research Institute, Kenilworth, NJ) in
patients with severe, remittent chronic plaque psoriasis in remission was
performed. Remission was achieved by conventional, standard intensive
anti-psoriatic therapy, including topical anti-psoriatics, such as anthralin
and calcipotriol in combination with ultraviolet (UV) radiation during
hospitalization (IL-10 pretreatment period). Including and excluding
criteria for the IL-10 therapy are shown in Table I. Thirty-nine patients
were screened for participation and 19 patients were included (Fig 1).
Eleven patients were unable to take part in the study due to the stringent
exclusion criteria. So evidence for an infection, mainly of the respiratory
tract (n = 7), presence of a hematologic, hepatic, or renal disorder
(n = 3), and pregnancy (n = 1) were found. Nine other patients refused
to enter into the study and did not sign the informed consent, and the
following reasons were speci®ed: the worry to be treated with a placebo
over a long period (n = 5), the wish to become pregnant (n = 1), and
general concerns about being treated with an unapproved drug and the
need for numerous investigations over a long period (n = 3).
Patients were randomized and received nonlesional subcutaneous
injections with either IL-10 (10 mg per kg bodyweight; group A, n = 8)
or placebo (group B, n = 11) three times a week. Before treatment no
signi®cant differences between the two groups were found with regard
to age, sex, and PASI. The age of psoriasis onset, however, was lower in
the placebo group (Table II). Besides IL-10 no other anti-psoriatic
therapies were used. Bland emollients (up to 5% carbamid in eucerin
cum aqua), however, could be applied topically.
Patients were treated for up to 4 mo (121 d). End-point beside the
end of planned treatment period (4 mo) was occurrence of a relapse,
which was de®ned as one of the following: (i) increase of the PASI to
values > 8; (ii) request by patients for further additional treatment even if
the degree of relapse was < 50% (according to the criteria by Levell et al,
1995); and (iii) other severe diseases, such as severe infections, develop-
ment of cancer, and hematologic disorders.
Figure 1. Study population.
Table I. Criteria for inclusion and exclusion of psoriasis
patients
Inclusion criteria
patients with known moderate to severe chronic plaque psoriasis
PASI > 10 before conventional anti-psoriatic treatment
preceding successful treatment with UV light, and/or topical
anti-psoriatics
remission (PASI < 5)
no obvious need for further treatment
history of frequent relapses
older than 18 y
written informed consent.
Exclusion criteria
clinical evidence for infection during 1 wk prior to the study
patients with double-stranded anti-DNA antibodies
patients with chronic viral diseases
patients with presence of cancer
patients with presence of hematologic, hepatic, or renal disorder
Karnofsky index < 70
pregnancy
platelet count < 100,000 per ml
systemic treatment with steroids 3 wk preceding the study
treatment with medicine considered to exacerbate or trigger psoriasis
(e.g., b-adrenoreceptor blockers, cyclooxygenase inhibitors, lithium)
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The study was approved by the Institutional Review Board of the
Medical Faculty, and written informed consent was obtained from all
patients.
Investigations Clinical examination was performed before therapy, at
1 wk after start of IL-10 treatment and at least twice a month
subsequently. The patients were interviewed with regard to side-effects.
An adverse event was de®ned as any change in the patient's baseline
condition, which occurred during the course of the study, regardless of
whether or not the event was related to treatment. Ef®cacy was
measured at baseline and every 14 d by the PASI scoring system
(Fredriksson and Pettersson, 1978). Relapse incidence and mean duration
of remission (time until occurrence of relapse) were determined in the
IL-10 and placebo groups to assess the clinical value of IL-10 long-term
treatment.
Blood samples were obtained before therapy, after 1 wk and thereafter
every 14 d for laboratory investigations. Paraclinical parameters to assess
safety of IL-10 treatment included the determination of hemoglobin,
hematocrit, red and white blood cell count, differential blood cell count,
mean corpuscular volume, mean corpuscular hemoglobin, mean corpus-
cular hemoglobin concentration, thrombocyte count, coagulation para-
meters, albumin, total protein, bilirubin, transaminases, alkaline
phosphatase, electrolytes (Na, Ca, and K), creatinine, urea, urea acid, and
glucose.
Investigations to assess the immunologic activity of IL-10 treatment
were performed at monthly intervals (before and on days 30, 60, 91, and
121) in all patients until study termination or relapse of psoriatic disease.
Plasma concentration of the soluble IL-2 receptor (sIL-2R), a parameter
that we have found to increase during IL-10 treatment in previous
studies (unpublished data), was determined by the semiautomatic
Immulite system (DPC Biermann, Bad Nauheim, Germany). For assess-
ing the impact of IL-10 on the T helper (Th)1/Th2 balance, interferon
(IFN)-g and IL-4 secretion was determined after 24 h concanavalin A
stimulation (100 mg per ml, Serva Feinbiochemica, Heidelberg,
Germany) in 1:5 prediluted heparinized whole blood. Cytokine levels in
pooled supernatants of duplicated tests were determined by IFN-g
enzyme-linked immunosorbent assay (Medgenix, Ratingen, Germany)
and Cytoscreen ultrasensitive IL-4 enzyme-linked immunosorbent assay
(Laboserv, Giessen, Germany) with the upper detection limits of 150 IU
per ml and 50 pg per ml, respectively.
Statistical analyses The mean duration of remission (i.e., time until
occurrence of relapse or if reaching the end-point of the study 121 d)
were determined and compared between the groups using the Mann±
Whitney test. The incidence of relapse was determined and compared
between the groups using the Chi-square assay. To determine the risk of
relapse, Kaplan±Meier analysis with the Log Rank Test was performed.
Moreover, for the early study period (day 7 and day 14, before drop out
of patients due to relapse) the PASI scores were compared with the
pretreatment values (Wilcoxon test) and between the two groups
(Mann±Whitney test). Differences were considered to be signi®cant at
p < 0.05. Pearson Product Moment Correlation was used for correlation
analyses. Data are presented as mean 6 SEM.
RESULTS
Tolerability Overall the treatment was well tolerated. Three of
eight patients in the IL-10 group and four of 11 patients in the
placebo group developed ¯u-like symptoms (rhinorrhea in six
patients, cough, hoarseness, mild headache). All these symptoms
were of minor severity and did not require interruption of the IL-
10/placebo therapy. It seems unlikely that their occurrence during
the long treatment period (4 mo) was related to the IL-10
administration as they were similarly observed in the IL-10 and
placebo groups and they disappeared within 1±2 wk despite
continuation of the treatment. Moreover, at the same time
relatives of the patients had similar symptoms, suggesting an
infectious origin. There was even a tendency for more frequent
side-effects in the placebo group as only in the placebo group one
single patient developed mild angina tonsillitis, another
hypertension, and a third patient nausea and vomiting.
In contrast to our ®ndings in the short-term IL-10 trial
(Asadullah et al, 1999c) none of the patients showed mild local
in¯ammation in the injection area.
When analyzing the safety laboratory parameters moderate
effects on the hematopoietic system were found. In the IL-10-
treated group leukocytes transiently decreased up to day 60 of the
treatment when they recovered. In the differential blood count a
decrease of the neutrophils (from 66.9 6 4.2% to 58.1 6 2.8% on
day 91 and 61.4 6 2.3% on day 121) was notable, whereas the
lymphocytes increased from 23.5 6 2.1% to 29.5 6 2.6%.
Hemoglobin, hematocrit, and erythrocyte counts did not change
signi®cantly during IL-10 therapy. There was no evidence for
signi®cant effects on electrolytes Na, K, and Ca. Renal and
hepatotoxicity were excluded. The value of urea decreased from
the beginning till day 121 from 24.6 6 2.7 to 16.7 6 3.4 mg per
dl, and creatinine values also went down. Albumin was slightly
reduced from 4.89 6 0.09 g per dl to 4.51 6 0.15 g per dl. Of the
transaminases only alanine aminotransferase showed a difference to
the placebo group. It decreased continuously during treatment
period (from 17.1 6 4.1 U per liter before to 9.44 6 1.5 U per
liter on day 91 and 10.3 6 1.68 U per liter on day 121).
Taken together constitutional symptoms and laboratory safety
parameters suggest a good tolerability of long-term low-dose IL-10
therapy.
One patient in each group withdrew from the study for private
reasons, without signs for adverse effects and without a relapse of
psoriatic disease; this was on day 91 for a patient of the placebo
group and on day 46 for a patient of the IL-10 group (Fig 1).
These two patients, who were included for the assessment of
adverse effects and tolerability, were excluded from the analysis of
the clinical and immunologic effects of IL-10 treatment.
Anti-psoriatic effects The individual courses of the patients are
shown in Fig 2(A). Five of seven patients in the IL-10 treatment
group and one of 10 patients in the placebo group reached the
4 mo (121 d) end-point without psoriasis relapse. The other
patients (two of seven in the IL-10 group and nine of 10 in the
placebo group) ful®lled at least one criteria for relapse.
Consequently, the relapse incidence was signi®cantly lower in
the IL-10-treated group (28.6%) than in the placebo group (90%)
during this 4 mo treatment period (p < 0.05 chi-square test). In
Kaplan±Meier analysis the risk of relapse was signi®cantly different
between the IL-10 and the placebo group (p = 0.022 Log Rank
test) as could be seen in Fig 2(B). Moreover, the mean duration of
remission (time until the occurrence of relapse) in the IL-10 group
was signi®cantly longer than in the placebo group (101.6 6 12.6 d
vs 66.4 6 10.4 d).
When analyzing the psoriatic disease activity in the early
treatment period (before drop-out of patients due to relapse), a
signi®cant increase in PASI score was observed in the placebo
group (before 1.85 6 0.27, 1 wk 2.48 6 0.4, 2 wk 361 6 0.8;
p < 0.05 vs before for both). The PASI also slightly increased in the
IL-10 group but the rise did not reach signi®cance level (before
1.16 6 0.2, 1 wk 1.74 6 0.2, 2 wk 1.9 6 0.3; p > 0.05). When
Table II. Baseline pro®les of psoriatic patients
Patients receiving
IL-10
Patients receiving
placebo
Patient number 8 11
Age (y)a 46.6 6 5.3 35.1 6 3.6
Sex ratio (male/female) 3:5 7:4
Age of onset (y)a 30.6 6 4.7 15.6 6 4.0b
PASI scorea 1.61 6 0.23 1.85 6 0.27
Prestudy treatment
UV phototherapy 8 10
Anthralin 4 6
Vitamin D analoga 2 1
Topical glucocorticoids 1 1
Methotrexate 1 1
Fumaric acid esters 0 1
aData are mean 6 SEM.
bp < 0.05, Mann±Whitney U test.
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comparing the PASI values of both treatment groups, the p-values
were 0.3 and 0.06 for day 7 and day 14, respectively.
Taken together IL-10 therapy decreased the incidence of relapse
and prolonged the disease-free interval in patients with chronic
plaque psoriasis in remission.
Immunologic effects Based on our previous IL-10 trials in
psoriatic patients we selected three parameters for monitoring
immunologic effects: the plasma concentration of sIL-2R and the
ex-vivo secretion of the Th1 cytokine IFN-g and the Th2 cytokine
IL-4.
We observed a strong, signi®cant increase of the sIL-2R plasma
levels in the IL-10 group (Fig 3A). Remarkably, the two IL-10-
treated patients, who developed a psoriasis relapse, almost com-
pletely lacked this sign for IL-10 in vivo activity.
When investigating the ex vivo mitogen-induced Th1/Th2
lymphokine secretion, a tendency for increasing IFN-g and
decreasing IL-4 secretion capacities paralleled the high relapse
incidence in the placebo group. In contrast, in the IL-10-treated
patients the sustained remission in ®ve of seven patients was
associated with an even slightly increasing mitogen-triggered IL-4
secretion up to 3 mo (Fig 3B, C). As a consequence the IFN-g/IL-
4 ratio increased in the placebo but not in the IL-10-treated group
(Fig 3D), due to a decreasing IL-4 secretion capacity in patients
without IL-10 and an increasing IL-4 production in IL-10-treated
patients. Likely due to the escalating drop-out of relapsing patients
from the investigations none of the alterations reached signi®cance
level between the groups. The relation between a high ex vivo IL-4
secretion capacity and the failing activity of the psoriatic disease
became even more clear, when we looked for the correlation
between IL-4 secretion and PASI score. In both groups a negative
correlation was found (placebo group r = ±0.284, p = 0.11; IL-10
group r = ±0.454, p = 0.007) resulting in a highly signi®cant
negative correlation between IL-4 secretion capacity and PASI
score for the entire study population (r = ±0.364, p < 0.006)
(Fig 4). This supports that the parameter chosen is indeed of
pathophysiologic relevance for the disease.
DISCUSSION
Psoriasis is a chronic self-perpetuating immune disease in which a
relative IL-10 de®ciency seems to be of crucial importance
(Asadullah et al, 1998). Recent analyses of the IL-10 promoter
polymorphism in psoriasis suggested that this IL-10 de®ciency
might have a genetic background (Asadullah et al, 2001b). Here we
show clinical safety and therapeutic ef®ciency of IL-10 long-term
treatment. Low-dose IL-10 application inhibited the rapid
reoccurrence of the skin lesions in patients with severe psoriasis
in remission. This suggests that IL-10 therapy may be a novel
approach for the prevention of relapses and the prolongation of the
disease-free interval in psoriasis. To our knowledge this is one of
the ®rst reports on IL-10 long-term therapy, and the capabilities of
IL-10 administration to inhibit the relapse of an immune disease.
It is unlikely that other factors than IL-10 application itself are
responsible for the different clinical courses between the IL-10 and
the placebo group. It is well known that established anti-psoriatic
therapies differ in their remission duration (Koo and Lebwohl,
1999). Analyses of the pretreatment before entry into the study,
however, excluded a signi®cant difference between the two groups
(Table II). Another important factor with impact on the relapse
rate is the age of onset. So, patients with an earlier onset of the
disease have a shorter remission duration. Although a signi®cant
difference in the age of onset between the groups was found, the
average age is rather low in both of them. Both groups mainly
consisted of patients with early onset of the disease; therefore, six of
eight IL-10-treated and 10 of 11 placebo-treated patients showed
an onset before the age of 40, resulting in a median age of 24 y for
the IL-10-treated patients and of 15 y for the placebo-treated
patients. Correlation analyses between the time until relapse and
the age of onset for the entire population (r = 0.297, p = 0.25,
n = 17) as well as for the two treatment groups (placebo:
r = 0.297, p = 0.40, n = 10; IL-10: r = ±0.24, p = 0.60, n = 7)
excluded a signi®cant correlation between the exacerbation during
the observation period and an earlier onset of psoriatic disease. The
high relapse rate in the placebo group re¯ects that only patients
with moderate to severe psoriasis and a history of frequent
exacerbations were included into the study.
It is likely that IL-10 exerts its anti-psoriatic activity by effects on
different cell populations, including T cells, antigen-presenting
cells, and perhaps keratinocytes as well as their mutual interactions.
Psoriasis is a T cell dependent (auto)immune disease, probably
initiated by presentation of so far unknown ``psoriasis-related
antigens'' by specialized cutaneous antigen-presenting cells
(Valdimarsson et al, 1986; Asadullah et al, 1999c). IL-10 is able to
suppress the antigen-presenting cell activity of monocytes, macro-
phages, and dendritic cells (Asadullah et al, 1999c). In fact,
depressed monocytic HLA-DR expression as well as tumor
necrosis factor-a and IL-12 secretion led to a lasting shift to a
type 2 cytokine pro®le (increasing proportion of the IL-4, -5, and
-10 producing T cells, selective increase in IgE serum levels,
depressed delayed type hypersensitivity reaction to recall antigens).
In agreement with this it was observed during this trial that IL-10
may enhance the IL-4 secretion capacity. Recently, it was reported
that successful UV therapy of psoriasis is associated with a
Figure 2. Clinical effects of IL-10 therapy. (A) Individual courses of
psoriatic disease. The patients dropped out of the analysis when ful®lling
the criteria for psoriasis relapse. (B) Kaplan±Meier analysis of relapse-risk.
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considerable increase of cutaneous IL-4 expression.1 Moreover,
preliminary data suggested ef®cacy of IL-4 application itself.2 This
may point to a key role of this cytokine in psoriasis. Our ®nding of
a strong negative correlation between the IL-4 secretion capacity
and the psoriatic disease activity, reported here, further supports
such a hypothesis. Finally, direct effects of IL-10 on keratinocytes
may have contributed to the clinical response. So, it has been
shown that the IL-10 receptor is expressed on keratinocytes and
that IL-10 in high concentrations inhibits the proin¯ammatory
cytokine synthesis and proliferation of keratinocytes in vitro
(BeÂcherel et al, 1995; Michel et al, 1997). Our recent in vitro
results, however, using corresponding concentrations of rhIL-10 as
detectable in plasma during therapy, suggest that the anti-psoriatic
activity of IL-10 is rather caused by modulatory effects on
circulating immune cells, which subsequently might in®ltrate the
skin, than by direct effects on human keratinocytes (Seifert et al,
2000).
Although the effectiveness of IL-10 application for the therapy of
established exacerbated immune diseases (psoriasis, in¯ammatory
bowel diseases, rheumatoid arthritis) has been suggested by early
phase 2 trials, the potency of this treatment seems to be overall
below that of other promising approaches such as the anti-tumor
necrosis factor-a strategies. So, a complete disease clearance is a
very rare event after IL-10 application, suggesting a relatively low
anti-in¯ammatory potential of this therapy. Moreover, a recent
report (Lauw et al, 2000) and our own recent unpublished
observations suggest even pro-in¯ammatory properties of IL-10.
In agreement with this it was observed that there was an increase of
the sIL-2R levels in IL-10-treated patients. Therefore, we conclude
that the impressive effects with regard to prevention of disease
relapse described here, re¯ect long-term immunomodulatory rather
than anti-in¯ammatory properties of IL-10. These immunomodu-
latory effects might be primarily responsible for the prolongation of
the disease-free interval that was observed. Such a hypothesis is
supported by recent data from animal and in vitro experiments,
demonstrating that IL-10 can induce the formation of regulatory T
cells with a major impact on the immunoregulation (Cottrez et al,
2000; Levings et al, 2001). Taken together, both clinical and
immunologic data suggest that IL-10 application seems to be more
attractive in a secondary prophylactic (prevention of relapse) than in
a therapeutic approach.
Our ®nding, that low-dose long-term IL-10 maintenance
treatment seems to be able to prevent the frequent relapse of skin
lesions in patients with severe psoriasis after intensive anti-psoriatic
Figure 3. Immunologic effects of IL-10
therapy. The plasma levels of soluble IL-2
receptor (A), the ex vivo secretion of IFN-g (B)
and IL-4 (C), and the resulting IFN-g/IL-4
secretion ratio (D) were determined in monthly
intervals during the observation period. Sample
numbers for the different time points are: before
7/9 (IL-10/placebo); 30 d 7/9; 60 d 5/7; 91 d 5/
2; 121 d 5/1. The sIL-2R plasma concentrations
were assessed by semiautomatic ImmuliteÔ system
(DPC Biermann). IFN-g and IL-4 secretion was
determined in cultures of 1 : 5 with RPMI
prediluted heparinized whole blood stimulated for
24 h (37°C, 5% CO2) with concanavalin A
(100 mg per ml). The tests run in duplicate. In the
pooled supernatants cytokine concentrations were
determined by Interferon-g ELISA (Medgenix)
and IL-4 ultrasensitive enzyme-linked immuno-
sorbent assay (Cytoscreen) with upper detection
limits of 150 IU per ml and 50 pg per ml,
respectively. The IFN-g and IL-4 secretion
pattern was quite similar after correction by
lymphocyte count (data not shown).**p < 0.01,
*p < 0.05 vs placebo group in Mann±Whitney
test.
Figure 4. Correlation of IL-4 secretion capacity with the disease
activity. The concanavalin A-triggered IL-4 secretion in whole blood
was monthly determined (for time points and method see legend for
Fig 3) in all patients until exacerbation or study termination. Overall 55
samples were available. Correlation analyses (Pearson) between psoriatic
disease activity (PASI) and the ex vivo IL-4 secretion capacity yielded a
negative correlation in both treatment groups (placebo r = ±0.28,
p = 0.11; IL-10 r = ±0.45, p = 0.007) resulting in a highly signi®cant
negative correlation for the entire study population (r = ±0.36,
p = 0.006). The single values for each group and the regression line for
all patients are shown.
1Walters I, Ozawa M, Trepicchio W, et al: Narrow band UVB
suppresses g-IFN and IL-12 and increases IL-4 production: in vivo
evidence of immune deviation in psoriatic patients. J Invest Dermatol
114:792, 1999 (abstr.)
2Thomas P, Ghoreschi K, Breit S, et al: IL-4-induced immune deviation
as therapy of psoriasis. Arch Dermatol Res 293:39, 2001 (abstr.)
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therapy, might be of importance as it may offer a new option to
reduce cost-intensive morbidity and hospitalization. It might be
speculated, that IL-10 could be equally effective in other entities,
such as rheumatoid arthritis, and transplantation, where the
bene®cial effects of IL-10 short-term application have been
observed already. Corresponding trials should be considered. To
investigate further the effect of IL-10 long-term treatment in
psoriasis as a new therapeutic concept, might be of particular
interest, as psoriasis may serve as a model for hyperin¯ammatory
autoimmune diseases. Moreover, in contrast to several other
disorders such as the above mentioned, disease activity is clearly
visible and therapeutic effects can be monitored easily. It has to be
determined whether the long-term safety pro®le of IL-10 is
superior to other alternatives currently in use such as cyclosporine
A or methotrexate. Although our preliminary data, obtained from a
rather small study population, are quite promising, additional
information based on data from larger populations are essential.
This work was supported by Essex Pharma, Germany/Schering Plough Research
Institute, Kenilworth, NJ.
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